SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2018 / Cilt: 48 - Sayı: 4

The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation

Arron Munggela FOMA
Davood JAFARI
Kamran ALIMOGHADDAM
Seyed Ahmad HOSEINIAN
Mehdi MAHMOODI
Mohammadreza OSTADALI
Azita TALEBZADEH BONAKDAR
Mir Saeed YEKANINEJAD
Ali Akbar AMIRZARGAR
Pages
794–804
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We founda survival association between the donor lacking and the recipient having group B KIR haplotypes, although this was not statisticallysignificant.Conclusion: This study suggests that we could exploit NK cell alloreactivity as a part of the optimization of donor selection and potentialimmunotherapeutic regimens to help facilitate good engraftment and reduce the risk of aGVHD incidence after allo-HSCT.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: After allogeneic hematopoietic stem cell transplantation (allo-HSCT), donor natural killer (NK) cells triggeralloreactions against potential recipient cells by their killer immunoglobulin-like receptors (KIRs).
📊
Key Findings & Data:This study investigated whetherKIR/HLA genotypes and KIR haplotypes of donors and recipients exhibit a critical function in the prevalence of acute graft-versus-hostdisease (aGVHD) and persistence of the graft after HLA-identical sibling allo-HSCT for patients with hematological malignancies.Materials and methods: We studied KIR and HLA genotypes in 115 related donors and recipients (56 patients with AML and 59patients with ALL) who had received allo-HSCT from HLA-matched sibling donors.
💡
Conclusion & Impact:We founda survival association between the donor lacking and the recipient having group B KIR haplotypes, although this was not statisticallysignificant.Conclusion: This study suggests that we could exploit NK cell alloreactivity as a part of the optimization of donor selection and potentialimmunotherapeutic regimens to help facilitate good engraftment and reduce the risk of aGVHD incidence after allo-HSCT.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: After allogeneic hematopoietic stem cell transplantation (allo-HSCT), donor natural killer (NK) cells triggeralloreactions against potential recipient cells by their killer immunoglobulin-like receptors (KIRs). This study investigated whetherKIR/HLA genotypes and KIR haplotypes of donors and recipients exhibit a critical function in the prevalence of acute graft-versus-hostdisease (aGVHD) and persistence of the graft after HLA-identical sibling allo-HSCT for patients with hematological malignancies.Materials and methods: We studied KIR and HLA genotypes in 115 related donors and recipients (56 patients with AML and 59patients with ALL) who had received allo-HSCT from HLA-matched sibling donors. We evaluated 17 KIR genes and some alleles,including their ligands, using the PCR-SSP assay.Results: KIR gene frequency results between donors and recipients showed that donors had more activating KIR than their recipients.Chi-square comparison of KIR genotype frequencies in donors versus recipients revealed a significant difference (P < 0.001). We founda survival association between the donor lacking and the recipient having group B KIR haplotypes, although this was not statisticallysignificant.Conclusion: This study suggests that we could exploit NK cell alloreactivity as a part of the optimization of donor selection and potentialimmunotherapeutic regimens to help facilitate good engraftment and reduce the risk of aGVHD incidence after allo-HSCT.

🔖

Cite This Article

FOMA, A. M., JAFARI, D., ALIMOGHADDAM, K., HOSEINIAN, S. A., MAHMOODI, M., OSTADALI, M., BONAKDAR, A. T., YEKANINEJAD, M. S., AMIRZARGAR, A. A. (2022). The impact of donor and recipient KIR genes and KIR ligands on the occurrence of acute graft-versus-host disease and graft survival after HLA-identical sibling hematopoietic stem cell transplantation. Turkish Journal of Medical Sciences, Cilt: 48 - Sayı: 4, 794–804. https://ajindex.com/articles/610314

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol 2007; 7: 340-352. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112: 4371-4383.
  2. Bishara A, De Santis D, Witt C, Brautbar C, Christiansen F, Or R, Nagler A, Slavin S. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor‐alloreactive T cells causing GVHD. Tissue Antigens 2004; 63: 204-211.
  3. Willemze R, Ruggeri A, Purtill D, Rodrigues CA, Gluckman E, Rocha V. Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation? Best Pract Res Clin Haematol 2010; 23: 283-290.
  4. Merindol N, Charrier E, Duval M, Soudeyns H. Complementary and contrasting roles of NK cells and T cells in pediatric umbilical cord blood transplantation. J Leukoc Biol 2011; 90: 49-60.
  5. Ruggeri L, Aversa F, Martelli MF, Velardi A. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self. Immunol Rev 2006; 214: 202-218.
  6. Gagne K, Brizard G, Gueglio B, Milpied N, Herry P, Bonneville F, Chéneau ML, Schleinitz N, Cesbron A, Folléa G. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 2002; 63: 271-280.
  7. Schellekens J, Rozemuller EH, Petersen EJ, van den Tweel JG, Verdonck LF, Tilanus MG. Patients benefit from the addition of KIR repertoire data to the donor selection procedure for unrelated haematopoietic stem cell transplantation. Mol Immunol 2008; 45: 981-989.
  8. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versushost disease biology and therapy. Nat Rev Immunol 2012; 12: 443-458.
  9. Matte CC, Liu J, Cormier J, Anderson BE, Athanasiadis I, Jain D, McNiff J, Shlomchik WD. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 2004; 10: 987-992.
  10. Jacobsohn DA, Vogelsang GB. Acute graft versus host disease. Orphanet J Rare Dis 2007; 2: 35. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M. Tumor necrosis factor-α blockade for the treatment of acute GVHD. Blood 2004; 104: 649-654.
  11. Bignon JD, Gagne K. KIR matching in hematopoietic stem cell transplantation. Curr Opin Immunol 2005; 17: 553-559.
  12. Bouchlaka MN, Redelman D, Murphy WJ. Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects. Immunotherapy 2010; 2: 399-418. Abdolvaha